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Abstract
Thrombosis of the portal venous system, although rare in
the general population, is commonly diagnosed in pa-
tients with specific underlying conditions including pro-
thrombotic diseases, cirrhosis, hepatobiliary malignancy,
and intraabdominal inflammation. Recent improvements
in imaging have played a fundamental role in increased
detection of portal vein thrombosis (PVT), frequently
reported in asymptomatic patients as an incidental
finding. Minimally invasive, endovascular therapy is a
medically rational option to achieve recanalization of the
portal vein as an adjunct to conservative medical man-
agement. This review focuses on the advances in imaging
modalities to diagnose, stage and follow-up PVT, and
gives a short overview of the available endovascular





The frequent and disseminated use of noninvasive liver
imaging methods has led to an increased detection of
thrombosis of the portal venous system. The thrombus
fills the lumen of the portal (PV), splenic (SV), and
superior and inferior mesenteric veins (SMV, IMV). It
can be anatomically diffuse or restricted to one vessel or
to some of its branches. Portal vein thrombosis (PVT)
refers to the partial or complete obstruction of portal
venous flow by a luminal clot, or to the presence of a
‘‘cavernous transformation’’, constituted by hepatopetal
collateral neovessels at the porta hepatis, that develop to
bypass the obstructed segment of the portal venous sys-
tem.
The prevalence of non-tumorous PVT in the general
population has been estimated to be about 1% based on
an autopsy series [1]. PVT is the second most common
cause of portal hypertension in the developed world. The
etiology of PVT varies [2, 3] and, frequently, is linked to
multiple concomitant factors [4]. Cirrhosis, hepatobiliary
cancer, and other local factors, such as surgery and
intraabdominal inflammation increase susceptibility to
PVT [2]. In non-cirrhotic, non-malignant PVT (also
termed extrahepatic portal vein obstruction—EHPVO)
[5], systemic factors, i.e., inherited and acquired pro-
thrombotic diseases or primary myeloproliferative dis-
orders, are often found and play a major pathogenetic
role [6, 7]. Recently, abdominal obesity has been sug-
gested as a possible additional risk factor [8].
Liver cirrhosis is currently recognized as a pro-
thrombotic condition [9, 10]. Among patients with cir-
rhosis, PVT is a more frequent event as compared to the
general population, and its prevalence is between 10%
and 25%, being the highest observed in decompensated,
Child C patients [11]. A large prospective study of pa-
tients with compensated Child A and B cirrhosis showed
a 1 and 5-year cumulative incidence of PVT of 4.6% and
10.7%, respectively [12]. This data is in line with the
concept that PVT risk increases upon worsening of any
of the components of Virchow’s triad, i.e., stasis (here
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represented by decreased portal venous blood flow
velocity) [13], hypercoagulability [10], and endothelial
damage [14].
Clinicians may suspect PVT in the setting of
abdominal pain, which can dominate the clinical fea-
tures, particularly when thrombosis is recent and
extending to the mesenteric venous system. In patients
with chronic PVT, suspicion is often raised by presence
of complications of portal hypertension (PH) such as
variceal bleeding, ascites, encephalopathy, and/or portal
cholangiopathy (PC), featuring jaundice or cholangitis.
In these cases, the differentiation from simple decom-
pensation of cirrhosis is key. Nevertheless, PVT is fre-
quently asymptomatic and incidentally identified on
imaging. This raised awareness of healthcare profes-
sionals aligned with the notable developments of imaging
technology has fueled growing knowledge in this com-
plex setting. This review aims to provide a comprehen-
sive outlook on the current role imaging plays in
diagnosing and treating this entity.
Classification
From an imaging perspective, PVT is primarily defined
based on structural characteristics such as location (PV,
SMV, or SV), degree of occlusion, presence of cavernous
transformation of the PV, signs of PH, PC or signs of
bowel ischemia. Recent classifications of PVT, such as the
commonly used Yerdel’s classification [15], have focused
primarily on anatomical findings, ignoring the functional
impact. The Baveno consensus conference on the man-
agement of portal hypertension is an interdisciplinary
(hepatology, radiology, surgery, pediatrics) international
expert meeting held every 5 years focusing on controver-
sial and unclarified aspects in this field. Given the com-
plexity of PVT, the expert panel opinion was to classify
PVT according to: site, presentation/timing, underlying
disease, and degree and extent of occlusion [5]. Whether
thrombosis occurs in the setting of cirrhosis or in the ab-
sence of cirrhosis is relevant information that should be
taken into consideration and PVT in the absence of cir-
rhosis should be defined as ‘‘EHPVO’’. A new structural
and functional classification of PVT in cirrhotic patients
has been recently proposed by the experts in PVT
belonging to the Baveno VI (2015) consensus conference
expert panel to uniformly report findings and to homog-
enize, stratify, and follow the natural history of this
heterogeneous group of patients [16]. This defines the
patient by the site, degree, presentation, and functional
relevance of the thrombosis, i.e., acute or recent versus
chronic with or without cavernous transformation of the
PV, and symptomatic with or without acute bowel ische-
mia versus asymptomatic (Table 1).
Imaging in diagnosis, risk
stratification, and planning
of management of PVT: description
of the available techniques
Imaging is the cornerstone of the diagnosis of PVT.
Ideally, an imaging method should inform on the pres-
ence or absence of thrombosis, and if PVT is diagnosed,
the report should contain anatomical and functional
pertinent information: thrombosis nature (thrombosis vs.
neoplastic invasion; see ‘‘Differentiating thrombosis
from tumorous invasion of the portal vein’’), thrombus
extension, estimation of timing/chronicity, presence or
absence of a local factor, presence or absence of com-
Table 1. New Anatomico-functional classification of portal vein thrombosis in cirrhosis. Adapted from Sarin et al. [16]
Terminology to be used Acronym
I-Site
Type 1: only trunk
Type 2: only branch
(2a): one branch
(2b): two branches
Type 3: Trunk and branches
II- Degree of portal vein occlusion
Occlusive: no visible flow in portal vein (PV) lumen O
Nonocclusive: flow visible in PV lumen NO
IIIa-Duration
Recent: first detection in previously patent PV, dilated PV, hyperdensea thrombus, absent, or limited collaterals R




If Recent Acute PVT (with or without bowel ischemia)
If Chronic Clinical manifestations of PH (variceal bleeding, ascites)




arefer to CT imaging
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plications such as ascites, and congestion or ischemia of
the bowel [7].
First level imaging should inform on the presence of
absence of thrombosis. Ultrasound (gray-scale and Doppler
imaging) is accurate to diagnose and exclude PVT and
should be used as the first-line imaging method. [17, 18].
Contrast-enhanced (ce) imaging (ce-computed tomography,
ceCT, or, if contraindicated, ce-magnetic resonance, ceMR)
should be considered on admission in patients presenting
with severe presentation, particularly insuspectedmesenteric
ischemia, or with known severe underlying disease (malig-
nancy; history of intraabdominal inflammation/surgery,
thrombophilia) or in whom ultrasound cannot be correctly
applied (visualization limits) [5, 17].
Furthermore, ceCT or ceMR should be used in pa-
tients who have been diagnosed with PVT by ultra-
sonography to achieve a thorough characterization
(anatomical staging, collateral mapping, detection of
local factors, and complications). Presence of gas in the
portal vein observed by any imaging technique should
prompt a strong suspicion of intestinal ischemia. Table 2
shows the main advantages and disadvantages of each
imaging method used in PVT diagnosis.
Ultrasonography
Gray scale (B-mode) ultrasonography (US) comple-
mented by color-doppler ultrasonography (CDUS) is
considered the first imaging examination to be performed
because sensitivity and specificity values are above 90%
[19]. It is well-tolerated, safe, inexpensive, readily avail-
able, repeatable and given its high negative predictive
value, if CDUS confirms PV patency, then no further
studies are necessary. The sensitivity of ultrasonography
for diagnosis of PVT partly depends on the expertise of
the operator, interpatient variability and stage of
Fig. 1. Fifty seven years old male with a known Child B
alcoholic cirrhosis of the liver who developed upper abdomi-
nal pain. An ultrasonography shows a complete acute
occlusion of the main trunk of the portal vein (arrows, A) with
only a few small collateralizing vessels in the Doppler ultra-
sonography (B). A CT scan of the same patient reveals
hypodense thrombotic material completely occluding the
main portal vein trunk (arrows in coronal view, C) as well as
the right and the left intrahepatic portal venous branches
(arrows in axial view, D).
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obstruction and has been reported to be 100% in Yerdel
stages 3 and 4, i.e., complete thrombosis of the PV with
involvement of the SMV [15]; ultrasound is however less
sensitive if thrombosis is limited to SMV.
On gray scale ultrasonography, PVT can be seen as
echogenic material within the PV lumen, occupying it
completely (Fig. 1) or partially (Fig. 2). PV can appear
dilated in the site of a complete and recent occlusion
(Fig. 2). The echogenicity of the clot is variable from
hypo-, iso- or hyperechoic, being a hypoechoic aspect
more commonly observed in recent PVT. Both CDUS
and pulsed (spectral) Doppler US can differentiate
complete occlusive thrombosis from parietal incomplete
thrombosis. Complete thrombosis is characterized by
complete lack of color filling and Doppler signals. Thus
Doppler techniques facilitate the US examination and
improve its accuracy. These techniques are usually used
in combination (Fig. 1).
Alternatively, lack of a normal PV and observance
of small tortuous vessels with hepatopetal flow lead to
the diagnosis of cavernous transformation of the PV
[19, 20] (Fig. 3). In patients with cavernous transfor-
mation of the PV or long-lasting EHPVO, morpholog-
ical changes of the liver, compensatory hypertrophy of
the hepatic artery and signs of portal hypertension
(splenomegaly; porto-systemic collaterals) are frequent
associated findings.
Endoscopic ultrasonography (endosonography) is
both sensitive and specific for PVT. It can detect small
and nonocclusive thrombi [21, 22]; however, this imaging
modality is only used in second or third instance when
diagnostic doubts persist after noninvasive imaging
studies.
In the last decade, contrast-enhanced ultrasound
(CEUS) has been introduced. The method is based on the
intravenous injection of ultrasound contrast agents,
Fig. 2. Partial (mural) thrombosis of the right (A and B) and
left (B and C) intrahepatic portal vein. The thrombotic material
is hyperechogenic in the B-mode image of the ultrasonogra-
phy (arrow) while a partial perfusion of the vessel is remaining
(A). A coronal CT view shows the hypodense thrombus in the
right portal vein (B). Partial thrombosis of the left intrahepatic
vein in another patient: the diameter of the vessel is enlarged
(measurement, C) and a contrast-enhanced magnetic reso-
nance imaging (ceMRI) depicts a partial thrombosis (dotted
arrow, D).
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which are gas microbubbles (e.g., sulfur hexafluoride;
octafluoropropane; Perfluorobutane) surrounded by a
lipid or albumin shell providing stability to the com-
pound [23]. The microbubbles are similar to red blood
cells in size and remain exclusively in the vascular system
(purely intravascular contrast agents). Upon insonation
Fig. 3. Chronic complete portal vein thrombosis with a web
of large collateral vessels along the contour of the portal vein
(arrow) but with no remnant of the portal vein (A). Cavernous
transformation of the PV (arrow) with strong blood flow (B).
Cavernous transformation (arrow) after a complete portal vein
thrombosis depicted with axial ceMRI (C) and coronal ceCT
(D). Early cavernous transformation of the PV about 4 weeks
after an acute episode of pain with formation of collateral
vessels (arrow) (E). Chronic portal vein thrombosis where
only a fibrous cord (arrow) instead of the portal vein (F).
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the microbubbles oscillate creating harmonics (non-lin-
ear behavior) which enhance echo signals that can be
detected by specific software, permitting perfusion visu-
alization at real time [23]. Given its improved sensitivity
of CEUS versus standard US in vascular evaluation,
CEUS has gained ground in diagnosing PVT in complex
cases (e.g., patients with decompensated cirrhosis who
can have a very slow flow in the portal vein that can be
erroneously confounded with PVT; patients with recent
liver transplantation) [24]. Furthermore, CEUS mark-
edly improved the characterization of PVT, and allows
differentiating thrombosis from malignant invasion of
the PV in patients with hepatocellular carcinoma (HCC)
[25, 26] (see ‘‘Differentiating thrombosis from tumorous
invasion of the portal vein’’).
Contrast-enhanced computed tomography
Conventional multislice, ceCT is the second most com-
mon imaging test to identify PVT after US and may be
the best method to define the anatomy of the vascular
changes. Multiphasic CT has four phases: pre-contrast,
arterial, portal and late. Attaining images at the adequate
time (portal phase) is mandatory to avoid pitfalls. Images
acquired during the late arterial phase are not ideal for
the diagnosis of PVT as this phase is too early for a full
contrast filling of the portal vein. In this phase, contrast
inflow phenomenon may lead to false-positive results as
well. Moreover, in case of reduced or slow portal vein
inflow (often observed in decompensated cirrhosis), a
delayed contrast arrival to the PV can lead to a false
appearance of a filling defect on CT (Fig. 4). To avoid
pitfalls during imaging, two situations must be distin-
guished. If only one contrast phase is being acquired, it is
recommended to acquire the portal phase about 10–15 s
later than the usual 60–70 s after contrast injection [18].
In the case that several contrast phases are acquired, as it
is usually the case for protocols for the imaging of the
liver and differentiation of focal liver lesions, a venous
phase should be obtained approximately 90 s after con-
trast injection. Comparing both the portal venous and
venous phase usually allows a differentiation between an
inflow phenomenon and a real thrombotic material
within the portal vein [18].
Typically, in non-contrast-enhanced CT, PVT is seen
as isodense to adjacent soft tissue. A hyperdense aspect
can be shown if thrombosis occurred within a month.
This elevated CT attenuation value has been attributed
to the protein fraction of hemoglobin in the clot [27].
Following intravenous administration of iodinated con-
trast on CT, a thrombus appears as a low density, non-
enhancing defect within the PV lumen [27]. Moreover,
dynamic CT shows a filling defect partially or totally
occluding the (Figs. 1, 2) vessel with rim enhancement of
the wall [27]. Additionally, ceCT can show peripheral
bands of parenchyma with higher density in the arterial
phase fading into isodensity in the portal phase, defined
as transient hepatic arterial difference (THAD). This
typically spares the juxta-hilar area where blood supply
from the cavernous transformation of the PV to the liver
tissue is sufficient [27]. Other signs include decreased
venous enhancement in the liver during the portal phase
Fig. 4. A 65-year-old patient undergoing a CT scan of the
abdomen due to an unclear lesion in the liver. In the portal
venous phase 60 s post contrast injection there is a hypo-
dense band close to the upper contour of the main trunk of the
portal vein (arrow, A). However, in the late phase of the
examination 180 s post contrast injection this is not seen any
more (arrow, B). Obviously, the hypodensity close to vessel
wall was due to an inflow phenomenon of the contrast med-
ium as the portal venous phase was acquired too early with a
still high contrast in the liver artery (black star in A). If avail-
able, late contrast phases should be compared with portal
venous phases before the diagnosis of a portal venous
thrombosis to avoid false-positive results.
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and enlargement of the thrombosed PV [27]. As for other
imaging modalities, indirect markers of PVT are the
presence of cavernous transformation of the PV or fi-
brous cord, porto-systemic collateral vessels and arteri-
oportal shunts [28] (Fig. 3).
Non-cirrhotic patients with cavernous transformation
of the PV can present hepatic morphological changes
described as ‘‘atrophy-hypertrophy complex of the liver’’
with a larger central part of the liver (segment IV and
caudate lobe). It can be speculated that the supply of
portal venous blood flow from the cavernous transfor-
mation is not sufficient in the subcapsular or peripheral
areas, leading to their atrophy and inducing compen-
satory hypertrophy of the remaining segments [29].
CeCT has added value to map the mesenteric vascu-
lature and to identify secondary bowel complications,
such as bowel ischemia, and to identify contributing
diseases like a malignant mass, loco-regional infection/
inflammation, or signs of cirrhosis.
The principal downfalls of ceCT imaging are the
necessity of administering considerable volumes of
potentially nephrotoxic iodinated contrast agents and
exposure to ionizing radiation. In this regard, the inci-
dence of contrast-induced nephropathy (CIN) is esti-
mated around 5% [30, 31]). In cases of pre-existing renal
failure or iodine intolerance, shifting to MR imaging is
reasonable. Given the concerns regarding high radiation
exposure, omitting the unenhanced scans could be an
effective strategy. This can be achieved by dual-energy
CT (DECT) with iodine quantification in tissues, which
offers a direct evaluation of vascularization, independent
of attenuation [32].
Magnetic resonance imaging
CeMR is a sensitive and specific technique (accuracy
close to 95%) [33] to detect partial PVT and occlusion of
the main portal venous vessels, and to map the por-
tosplenic collaterals. Unenhanced T1- and T2- weighted
sequences are not ideal for the diagnosis of PVT, sug-
gesting that the thrombus signal intensity varies based on
the sequences used, theoretically resulting from the age
of the thrombus or the low intrinsic contrast of these
images compared with post contrast images. Flow arti-
facts have also been shown to be problematic on non-
contrast images.
Therefore, it is consensual that the use of contrast
images for the diagnosis of PVT is essential. The clot
appears isointense to hyperintense on unenhanced T1-
weighted images, and usually has a more intense signal
on T2w images, while older clots appear hyperintense
only on T2-weighted images (Fig. 2). Also, gradient-echo
MR might help to better evaluate any equivocal findings
on spin-echo MR image [34]. The main difference be-
tween non-thrombosed diminutive PV resulting from
cirrhosis and recanalized chronic thrombosis is the in-
creased wall thickness of the PV in the setting of
recanalization [33].
As for the safety of gadolinium-based contrast agents
(GBCAs), there had been many concerns about the onset
of nephrogenic systemic fibrosis (NSF) as a result of the
release of gadolinium from the complex structure [35].
Recent research largely restored the confidence in the
safety of GBCAs has been widely restored. It has been
shown that the development of NSF can be largely
avoided by avoiding GBCAs with a linear an less
stable structure in patients with chronic kidney disease
stages 4 and 5, or using more stable macrocyclic GBCAs
[36, 37].
MRI-true fast imaging with steady-state precession
(true FISP) might overcome the need for a contrast agent
administration, the difficulty of contrast injection in
cases of poor venous access and the degradation of the
images by respiratory motion. To surpass these limita-
tions, recent studies have demonstrated the efficacy of
non-ceMR portography in the diagnosis of PVT. Non-
ceMR angiography can depict the PV with the combined
usage of a respiratory-triggered three-dimensional (3D)
balanced steady-state free precession (bSSFP) sequence
and a time spatial labeling inversion pulse (T-SLIP) [38].
The application of Half-Fourier fast spin-echo scanning
with T-SLIP enabled selective visualization of the PV
without an exogenous contrast agent in healthy individ-
uals [38]. This provides a high signal-to-noise ratio
(SNR) per unit time and can produce an image with high
resolution. Balanced SSFP allows visualization of the
vessels without the use of an intravenous contrast agent
in a short acquisition time [39]. Recently, a study showed
that the flow-out method produced high-quality images
of the intrahepatic PV and peripheral branches during
free breathing without an exogenous contrast agent [40].
Diffusion-weighted MR imaging (DW-MRI) that can
also be applied in the liver is based on the Brownian
motion of water within different tissues [41]. Tumor tis-
sue usually contains a high cellularity with densely
packed tumor cells with a decrease in extracellular spaces
that lead to a restricted diffusion [42]. DW-MRI consists
of an acquisition of at least two b-values (in the liver
usually three values: 50, 300 and 800 s/mm2) which al-
lows the calculation of apparent diffusion coefficient
(ADC) maps. In tissues with tightly packed cells like
malignancies, Brownian motion is less than in an envi-
ronment with a lower degree of compartmentalization
and therefore diffusion is impeded, appearing bright on
DW-MR images and darker in the ADC map [43]. The
extent of diffusion impediment can be analyzed qualita-
tively on the ADC map and can also be measured
objectively.
Magnetic resonance cholangiopancreatography
(MRCP) is the technique of choice to be applied upon
suspicion of bile ducts abnormalities which can occur as
a result of long-lasting cavernous transformation of the
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PV (see ‘‘Mapping collaterals and identifying and grad-
ing portal cholangiopathy’’ and Table 2).
Indirect intraarterial portography and direct
transparietal access
The invasive angiographic approach is reserved for rare
cases with equivocal results on noninvasive imaging. In
the management of symptomatic splanchnic venous
thrombosis, it is used in conjunction with endovascular
therapeutic procedures (see below).
Specific questions with clinical
implications to be addressed
by imaging on diagnosis
and in the follow-up
Differentiating thrombosis from tumorous
invasion of the portal vein
Tumorous invasion of the portal vein is commonly
associated with hepatocellular carcinoma, particularly of
the infiltrative type, and can occur in other intrahepatic
and extrahepatic cancers, which should be always
investigated and ruled-out in patients with newly diag-
nosed PVT. The diagnosis of malignant PV invasion has
very relevant prognostic and therapeutic implications
(e.g., exclusion from LT program in patients with HCC)
and attention should be paid to signs that can help dif-
ferentiating between thrombosis and tumorous invasion
in patients with known HCC. Signs suggesting tumour-
ous invasion on any imaging method include direct
visualization of a tumoural mass adjacent to the PV,
disruption of the walls of the vessel and diameter
exceeding 23 mm [25]. Hyperenhancement in the arterial
phase and washout in the delayed phase are typical fea-
tures of HCC and HCC-related PV invasion on CEUS
(Fig. 5), ceCT, and ceMR. CDUS and spectral Doppler
can sometimes directly visualize arterial vessels within
the material filling the portal vein (Fig. 6), but have a
limited accuracy (sensitivity 82.5%; specificity 100%).
CEUS has accuracy close to 100% [25, 26]. CeCT might
show the typical ‘‘thread and streak pattern’’ [28], but
Fig. 5. Contrast-enhanced ultrasound revealing a tumor invasion of the main trunk of the portal vein with an initial ‘‘wash-in’’ of
contrast medium (arrows in A and B) followed by a ‘‘wash-out’’ afterwards (arrows in C and D).
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due to its limited time-resolution it might miss the arte-
rial hyperenhancement. The quantification of thrombus
iodine density in the portal venous phase by dual-energy
multi-detector CT with iodine quantification appears as
a promising new imaging technique for distinguishing
between thrombosis and neoplastic portal vein thrombus
material [44, 45].
Regarding MRI for differentiating thrombosis vs.
neoplastic invasion, T2-weighted imaging is a powerful
tool as tumor thrombi frequently have a heterogeneous
signal and a hyperintense appearance in T2- weighted
images. A subsequent confirmation can be obtained by
an uptake of contrast medium in dynamic fat saturated
T1-weighted imaging. A pilot study suggested that DW-
MRI can differentiate thrombosis from neoplastic inva-
sion material [46]. In this study, neoplastic thrombosis
showed low ADC values in the ADC map which were
similar to those observed in HCC (Fig. 6). On the con-
trary, thrombosis showed high ADC values [46]. How-
ever, other studies revealed that signal-intensity
characteristics on DWI and measured ADC values do
not differentiate benign from malignant PVT reliably [47,
48].
Fine needle biopsy of the thrombus either percuta-
neously [49] or during endosonography [50] can be safely
performed in doubtful cases to achieve a final diagnosis.
Diagnosing/excluding cirrhosis
Patients with liver cirrhosis are prone to develop PVT,
and a reduced PV flow velocity (i.e., <15 cm/sec) is an
independent predictor of the development of PVT [13] in
this population. In patients with newly diagnosed PVT,
the diagnosis of cirrhosis should be always taken into
Fig. 6. A 55-year-old patient with a known hepatocellular
carcinoma (HCC) that is diffusely infiltrating the liver par-
enchyma in the liver segments II, III, and IVa/b. An ultra-
sonography shows a widening of the portal vein that is filled
with hyperechogenic tumor mass (A). Doppler ultrasonogra-
phy reveals a vascularization of the tumor mass with arterial
vessels (circle, B). Diffusion-weighted MRI (DW-MRI) has a
high signal in the b800 image within the tumor tissue (arrow,
C). The corresponding ADC map shows a low signal indi-
cating a high diffusion restriction due to tightly packed tumor
cells (arrow, D).
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consideration. Imaging signs of cirrhosis include liver
surface nodularity on ultrasound [51] or CT [52], as well
as morphological changes (caudate lobe hypertrophy;
atrophy of the right liver lobe; curling of hepatic veins).
However, similar changes can be observed in patients
with long-lasting chronic PVT (Fig. 1), and should be
considered not 100% specific in this setting. Liver stiff-
ness measurement by ultrasound elastography provided
a new effective tool to support the diagnosis of cirrhosis
vs. non-cirrhosis with over 90% accuracy [53]. Liver
stiffness is typically increased in patients with cirrhosis
and normal or almost normal in patients with PVT [54].
Discriminating between recent/acute and chronic
PVT
Distinguishing between a recent and chronic setting is
pertinent to decision-making regarding the optimal
therapy, which is aimed at achieving recanalization and
avoid thrombus extension. Recent/acute PVT shows a
higher rate of recanalization after anticoagulation in
comparison to chronic thrombosis [7, 55]; furthermore,
persistence or absence of a portal remnant is crucial to
plan an eventual transjugular intrahepatic porto-sys-
temic shunt (TIPS) and to attempt PV recanalization.
The natural progression of PVT is a dynamic process
that extends from recent thrombus to cavernous trans-
formation of PV with further progression to the intra-
and extrahepatic porto-mesenteric venous system. This
course can occur in a few days from partial to complete
obstruction, to fibrotic cord, finalizing in 3–5 weeks.
Cavernous transformation of the PV development could
occur between 6 and 20 days after an acute onset and
once cavernous transformation of the PV is detected,
patients are regarded as having entered the chronic stage
[5]. Complications, namely, signs of PH and portal
cholangiopathy (PC) are detected subsequently, in later
stages. The presence of calcifications within the wall of
the vessel or the thrombus is a pathognomonic finding
that can only be seen using US or CT (Fig. 7), but not
MRI. Furthermore, in non-cirrhotic patients without
underlying hematological disorders, an acute onset can
be supported by the absence of porto-systemic collaterals
and a normal or mildly increased spleen size. There are
certain situations where it is unfeasible to determine the
age of the thrombus, such as when a hypoechoic com-
plete or partial thrombus is detected in a vessel without
collaterals and with a normal size.
Mapping collaterals and identifying and grading
portal cholangiopathy
CeCT is the technique of choice to map the porto-sys-
temic and porto-portal collateral vessels. Post-processing
tools such as maximum intensity projection, volume
rendering and surface shaded display are useful adjuncts
to map the system of porto-portal and porto-systemic
collaterals, and study their relationship with the bile
ducts [56]. A direct compression of the cavernous
transformation of the PV on the intra- and/or extra-
hepatic biliary ducts can lead to obstruction and dilata-
tion, and gallbladder abnormalities which is termed
‘‘portal cholangiopathy’’ (PC) or ‘‘portal biliopathy’’ [56,
57]. It is diagnosed in imaging in over 80% of patients
with EHPVO, but clinical consequences such as chole-
cystitis, cholangitis and jaundice are uncommon [57].
Abnormalities of the biliary tree can be classified into
different degrees of severity: no abnormalities; grade I
(irregularities or angulations of the biliary tree); grade II
(indentations or strictures without dilation); and grade
Fig. 7. A 45-year-old patient with an acute partial throm-
bosis of the portal vein close to the confluens in a former
CT scan from the year 2010 (arrow, A). A follow-up CT
scan in 2016 shows an extensive calcification of the
thrombotic material along the course of the portal vein
(arrow, B).
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III (strictures with dilation; biliary dilation if intrahep-
atic ducts > 4 mm or extrahepatic duct > 7 mm) [57].
Severe PC developed in 30% of patients with acute PVT
within 1 year [57]. Major differential diagnoses of PC
include hilar cholangiocarcinoma and primary sclerosing
cholangitis, which should always be carefully excluded
[56]. Whilst US and CT can visualize PC, MRCP remains
the modality of choice for its complete characterization.
MRCP should be performed at diagnosis in patients with
chronic PVT and after 9–12 months of acute PVT if
recanalization is not achieved with AC. If grade III
portal cholangiopathy has not developed at the
12 month of follow-up, no further examination is nee-
ded, as progression is unexpected [57]. Endoscopic ret-
rograde cholangiopancreatography is reserved only for
those requiring therapeutic intervention. Endoscopic
ultrasonography (EUS) is not routinely employed and is
generally recommended only when differentiation be-
tween fibrous collateral tuft, stones, and tumors is
impossible with other modalities [58].
Role of imaging in treatment
Medical therapy
Anticoagulation (AC) with vitamin K antagonists or
with heparins is the current mainstay of treatment of
PVT. Besides achieving recanalization in 39%–80% of
Table 3. Most commonly reported indications, advantages, and disadvantages of the main endovascular treatment modalities used in patients with
acute or chronic PVT
Indications Advantages Disadvantages
Thrombolysis
Directa (transhepatic or transsplenic)














– Relatively easy and fast
– Treat small tributary
mesenteric thrombosis
– Can be used as adjunct to
the direct technique
– High risk of bleeding from the
access site
– Less dose delivery vs. indirect
– Allows to combine
thrombectomy
angioplasty/stent
– Higher dose of thrombolytic
agent required, and conse-
quently increased systemic
toxicity/risk of bleeding vs.
direct technique
– Increased infusion time
– Does not allow to combine
thrombectomy/ angioplasty/
stenting with the same access









– Safe in patients with high
risk of bleeding
– If combined to thrombol-
ysis: shorter thrombolysis
dose and time
– Increased lesion of vessel and
re-thrombosis











– Can be attempted
in chronic PVT if
a remnant of the








– Previous TIPS with
re-thrombosis or
extension to SMV
– Lower bleeding risk vs.
direct transparietal and
transsplenic approach
– Allows to combine
thrombolysis and
thrombectomy
– TIPS placement: allows
for faster recanalization
of thrombosis (fast flow)
and resolves PH
– Usually long procedure
– Risk of arrhythmias (catheter
pass in the right atrium)
– Need for ultrasound guidance
to the thrombosed portal
vein
– Risk of liver capsule puncture
(intraperitoneal bleeding)
and hemobilia low but not
inexistent
– Risk of intrahepatic hemato-
ma
– In chronic PVT: technically
challenging procedure,
requiring specific expertise
aballoon angioplasty and stenting can be combined if needed
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cases, it avoids progression, re-thrombosis, and sec-
ondary complications [5, 17].
The use of direct oral anticoagulant drugs (DOACs,
such as, rivaroxoban, dabigratan, apixaban) has been
growing in the context of PVT, revealing efficacy, and
safety [59, 60]. However, DOACs remain off-label in
patients with PVT and their use in patients with
decompensated cirrhosis is contraindicated due to
insufficient data. Permanent AC should be offered in
cases of prothrombotic conditions, or in PVT extending
to the SMV, as the benefits clearly outweigh the risks
[17]. Continued AC in transplant candidates is recom-
mended. In patients not responding to AC or when the
SMV is affected, alternative therapeutic options should
be considered [17].
Recanalization on AC is not universal and usually
does not occur beyond the first 6 months of therapy.
Furthermore, bleeding risks are not negligible. There-
fore, an accurate follow-up on imaging is needed to guide
clinical decisions whether to keep or suspend AC.
Minimally invasive vascular techniques
Table 3 clarifies the main reported indications, advan-
tages and disadvantages of the principal endovascular
treatment modalities. Imaging plays a crucial role on
taking the decision of attempting endovascular treat-
ment. A remnant of intrahepatic portal vein is required
to attempt a transhepatic approach, and in the authors’
experience the use of ultrasound improves the selection
of patients in whom portal vein access can be successfully
achieved. On the other hand, a complete and extensive
cavernomatous transformation of PV, SV, and SMV
prevents an endovascular treatment.
Direct access to the portal vein can be achieved by
different approaches, namely (a) percutaneous tran-
shepatic puncture; (b) percutaneous transplenic punc-
ture; (c) transjugular intrahepatic puncture.
Transileocolic, and omental vein approaches are rarely
performed [61]. The access to the portal vein can take
advantage of ultrasound guidance. Percutaneous transs-
plenic approach is reserved for patients for whom con-
ventional transhepatic or transjugular intrahepatic
approaches are difficult or unfeasible, as it carries a
higher risk of bleeding.
In contrast to the transjugular, transhepatic access in
a non-thrombosed PV, sonographic guidance is needed
for safe access a thrombosed PV system.
No head-to-head studies comparing endovascular
techniques with anticoagulation and recanalization with
vs. without thrombolysis are currently available.
Thrombolysis
Catheter-directed thrombolytic (CDT) therapy with or
without thrombectomy has been proposed for patients
with thrombus extension or worsening symptomswhile on
therapeutic AC, and in patients with impending or ongo-
ing bowel ischemia due to thrombosis, in cases with an
acceptably low risk of bleeding. Local clot dissolutionwith
low-dose thrombolytic therapy (e.g., 1 mg/h rt-PA for a
max of 48 h) is effective and safe with low risk of bleeding
[62]. Infusion involves placement of a 4 or 5 Fr infusion
catheter with multiple side holes across the thrombus. A
thrombolytic agent is administered through the catheter
Fig. 8. Isolated acute intra- and extrahepatic portal vein
thrombosis in a patient with liver cirrhosis candidate to liver
transplantation. A Direct portography, using the transjugular
intrahepatic porto-systemic shunt (TIPS) access with com-
plete thrombotic occlusion of the portal vein down to the
confluens (arrow), porto-systemic pressure gradient (PPG)
22 mmHg. After thrombus fragmentation using a Dormia 
basket, thrombus aspiration and intrahepatic Viatorr stent
insertion (TIPS) the common portal vein as landing zone for
transplantation was free of thrombus. B Completion portog-
raphy with brisk contrast flow via common portal vein (arrow)
and TIPS (arrow head), PPG 4 mmHg.
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andheparin is administered through the sheath [61].Direct
percutaneous transhepatic or transsplenic portal venous
accesswithout TIPS is uncommon as it lacks restoration of
brisk venous outflow. The method of choice is the tran-
sjugular, transhepatic access to reach the porto-mesenteric
thrombus, followed by transhepatic stent placement
(TIPS) to enhance venous outflow. This method is more
efficient, faster, and requires lower doses of thrombolytic
agent, in comparison with the indirect approach in which
thrombolytic agents are administered into the superior
mesenteric artery through the femoral or radial artery. The
combination of mechanical thrombectomy with CDT
(PMCT) has the advantage of lysing smaller thrombi not
targeted by mechanical thrombectomy. Thromboses of
both portal and mesenteric veins are typically associated
with more congestion and fewer collateral vessels, suggest
that loco-regional CDT are favorable in these circum-
stances. Main reason of CDT treatment failure is the low
likelihood of dissolution in cases of significant thrombus
organization. The choice of thrombolysis agent should be
considered with local urokinase or alteplase (rt-PA) in
combinationwith unfractionated heparin. Post-procedure
continuous oral AC therapy and close imaging surveil-
lance are indicated.
Thrombus fragmentation and thrombectomy
Thrombus fragmentation to destruct the clot (for more
efficient thrombolysis) can be achievedmechanically, with
pigtail catheter, balloons, or special devices such as Dor-
mia baskets or suction techniques [63]. Aspiration of the
fragmented thrombus can be performed using 8 Fr aspi-
ration catheter or dedicated large sized thrombectomy
devices. Thismethod is primarily indicated in patientswith
high hemorrhagic risk or relative contraindications to
thrombolytic agents.When used in conjunctionwith CDT
(pharmacomechanical thrombolysis, PMCT), it decreases
the required dose of alteplase and the need for prolonged
infusion [64]. Nonetheless, there is a risk of vessel injury
and re-thrombosis [65]. Pulmonary embolism and brady-
chardia related toPMCThave beendescribed if performed
after stenting of the transhepatic access (TIPS) to increase
venous outflow.
Angioplasty and stenting
Balloon angioplasty and stenting are meaningful in case
of residual/refractory thrombosis and stenosis of the
porto-mesenteric venous system, with or without previ-
ous thrombolysis/thrombectomy. In cases of tumorous
invasion of the PV, palliative stents, particularly self-
expanding, can be effective.
Transjugular intrahepatic porto-systemic shunt (TIPS)
The transjugular, transhepatic porto-systemic (TIPS)
(Fig. 8) access has a clear advantage over direct tran-
shepatic or transsplenic access in patients with ascites,
splenomegaly, or coagulopathy. It is, therefore, preferred
in patients with PVT, cirrhosis and PH. The bleeding risk
is lower as compared to direct transhepatic or transs-
plenic access and it provides access for embolization of
the esophageal and gastric varices. After TIPS, PH is no
longer present and flow velocity through the portal sys-
tem is increased, reducing recurrence of PVT [66]. In
patients with extensive PVT and bowel ischemia, en-
dovascular CDT is usually combined with a TIPS pro-
cedure to increase venous outflow.
In patients with chronically occluded PVT, TIPS
placement is challenging. Transsplenic PV recanalization
followed by TIPS is a potentially safe and effective
method to treat chronic PVT and improve transplant
candidacy [67]. This route might be considered in pa-
tients in whom standard approaches are unsuccessful,
but it carries a higher risk of bleeding.
In complex cases, a superior mesenteric arteriography
may assist in mapping the anatomy and delineating a
treatment plan.
AC therapy is normally maintained after TIPS in
patients with PVT and cirrhosis. In the only randomized
controlled trial available comparing TIPS + AC vs.
TIPS only in this population (either acute or chronic),
both strategies showed a high 12-month patency rate
(83.9% in the combination vs. 71.8% in TIPS only,
p = 0.25) [68].
Role of imaging in patient follow-up
Imaging is a crucial tool in monitoring the complications
of portal hypertension and the response to AC. When-
ever a major episode of decompensation (e.g., variceal
bleeding), ceCT, or ceMR should be performed to eval-
uate possible re- thrombosis episodes, plot the patent
vessels, and porto-systemic collaterals (commonly ecto-
pic), and, ultimately, to assess whether endovascular
procedures (e.g., TIPS; embolization of collaterals) or
shunt surgery are technically feasible [17]. On follow-up,
images should be always compared to the previous ones,
and both recanalization and re-thrombosis/new throm-
bosis should be clearly reported to facilitate clinical
decisions.
Since recanalization of the PV occurs up to 6 months
after AC, a follow-up imaging study after 6 months of
AC is recommended [17]. The first imaging technique
used upon starting AC should be used [17]. After this
first re-assessment, there is no consensus on which
technique and interval should be used, and follow-up
should be individualized according to the patient’s risk
factors, the institution’s experience and risks of repeated
use of radiation and iodinate contrast [17, 18]. However,
it should be considered that recanalization of splenic vein
and mesenteric veins can take longer than 6 months,
Therefore, in patients presenting with SV and/or SMV at
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our institution we consider useful a further assessment at
12 month either by ceCT or ceMRI [7]. It is important
therefore to remark that whenever technically feasible
(good ultrasound visualization) CDUS should be used to
follow-up patients with PVT.
Conclusions
As described in this review, imaging has a fundamental
role in the diagnosis and management of patients with
PVT. Imaging contributes to promptly identify and
characterize thrombosis, detecting the underlying dis-
ease/conditions and improving prognostic stratification,
all crucial aspects that should be taken into consideration
on attempting recanalization. Endovascular techniques
offer the ability to restore PV patency, and should be
considered in acute/recent PVT when thrombosis is
refractory to AC and when complications of PH have
already developed. After treatment, imaging follow-up is
the key to identify patients progressing despite first-line
therapy with AC, and to monitor maintenance of pa-
tency in patients in whom AC is stopped. Lack of high-
quality evidence is a major problem to guide therapy in
this field. Future well-designed prospective studies
should provide evidence to define the best therapeutic
algorithm for acute and chronic PVT. Due to the com-
plexity and severity of this condition, a multidisciplinary
approach with hepatologists, diagnostic radiologists,
interventionalists and surgeons is critical to elaborate a
standard diagnostic and therapeutic protocol and to
ensure successful outcomes.
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